NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









ReNetX Bio

ReNetX Bio

Private
New Haven, ConnecticutHealthcare & Life Scienceshttps://renetxbio.com

Last Round

Series A

Extension

Sep 30, 2020

Total Funding Raised

$1M

Company Overview

ReNetX Bio is a biotechnology company that develops first-in-class therapeutics to treat injuries and damage to the central nervous system, including spinal cord injury, stroke, and glaucoma.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biotechnologynerve regenerationspinal cord injuryCNS therapeuticscentral nervous systemaxonal regenerationtherapeutic proteinneuroregenerationclinical-stage biotechbiologics developmentdrug discoveryclinical trialsregenerative medicineneurological disordersCNS repair

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

ReNetX Bio Comparables

Compare ReNetX Bio with similar companies based on industry and business-model similarity.

ReNetX Bio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
BioAxone BioSciences
82%
Neuroplast
82%
NervGen Pharma Corp.
81%

ReNetX Bio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series A ExtensionSep 30, 2020
Series AMay 8, 2018
Convertible DebtJul 10, 2014
Corporate FundingMay 1, 2012

ReNetX Bio Investors

Notable investors and investment history

ReNetX Bio investors
InvestorRounds
Connecticut InnovationsConvertible Debt, Series A Extension, Series A
Wings for Life FoundationSeries A
Spring Mountain CapitalSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 1, 2012

    AstraZeneca participated in the round.

ReNetX Bio Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

ReNetX Bio Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about ReNetX Bio's valuation, stock price, and market status.

Firmographic Details

HeadquartersNew Haven, Connecticut
Year Founded2010
Last FundingSep 30, 2020

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.